FORWARD LOOKING STATEMENTS

TEAM

- Dr. Carl Schwartz   Chief Executive Officer   Predictive Oncology Inc.

- Bob Myers   Chief Financial Officer   Predictive Oncology Inc.

- Mark Collins, Ph.D   Chief Technical Officer   Helomics Corporation

- Richard Gabriel   President   TumorGenesis Inc.

- Larry DeLucas, Ph.D   Founder   Soluble Biotech Inc.

- Keith Champion, Ph.D   Director of Operations   Soluble Biotech Inc.

WHO WE ARE

PREDICTIVE ONCOLOGY®

Helomics
Our 2019 acquisition of Helomics provided a key proprietary technology platform and data pipeline for Predictive Oncology to be a leader in providing next-generation, AI and data-driven services to Pharma and Diagnostic companies to accelerate the development of new precision therapies

TumorGenesis
TumorGenesis focuses on developing an approach to grow tumors in the laboratory that mimics the patient's body. This platform, along with other proprietary, FDA-approved technologies merged from the Helomics purchase, will be used to fuel unique and more clinically actionable data for our predictive models

Soluble Biotech
Soluble Biotech's Unique Technology Platform is designed to rapidly optimize pharmaceutical formulations needed to deliver protein-based therapeutics and vaccines to the market

Skyline Medical
Selling the new standard in waste fluid management. The revolutionary, FDA-approved Streamway System is an automated, direct-to-drain system that's changing the way healthcare facilities collect and dispose of potentially infectious waste fluid.

HELOMICS

Helomics

uniting patients and therapy through knowledge

We leverage our proprietary big data and AI platform to deliver more precisely targeted therapies for patients

For BioPharma

- We improve the efficiency and cost effectiveness of the discovery of new drugs

For Clinicians

- We help oncologists individualize current therapies for patients

The Need

The Biopharma industry needs to improve the efficiency and cost effectiveness of drug discovery which accounts for **one-third** ($700M) of the overall cost of a new drug

R&D returns have fallen to the **lowest level** in **nine years**

2010
10.1%

2011
7.6%

2012
7.3%

2013
4.8%

2014
5.5%

2015
4.2%

2016
4.2%

2017
3.7%

2018
1.9%

The cost to bring an asset to market has **increased** to **record levels** in 2018

$2,168m

$1,188m

2010   2018

Late-stage pipelines increasingly comprised oncology

2010

18%

Forecast peak sales per asset have **more than halved** since 2

2010
$816m

2018
$407m

Deloitte(2018) Unlocking R&D productivity. Measuring the return from pharmaceutical innovation 2018

The Opportunity

Use Artificial Intelligence (AI) to improve **accuracy**, **predictability** and **speed** of Biopharma R&D

- Reduce time, and increase agility of the drug discovery process
- Increase accuracy of efficacy and safety of drugs
- Improve diversity of drug portfolio

AI-driven big biopharma deals disclosed in the market

Number of deals

Pfizer	Takeda	Sanofi	Roche	Merck	AbbVie	Janssen	GSK	Novartis	Boehringer Ingelheim	Novo Nordisk	Bayer	Amgen	Eli Lilly	AstraZeneca	Bristol-Myers Squibb	Gilead Sciences	Teva	Allergan
5	5	5	4	4	4	3	3	2	2	1	1	1	1	1	1	1	1	1

*Source Deloitte Insights. March 2019. Intelligent Drug Discovery

AI in drug discovery market by the numbers
- $700M (2018)
- $20B (2025) – 30X growth
- Most major biopharma pursuing AI solutions
- Lots of companies in the space but biopharma making multiple deals*
- Trend to outsourcing to Contract Research Organizations (CRO)

Helomics Intelligent Drug Discovery

- The world's largest patient tumor drug response and genomic knowledgebase gained from testing of 150,000 clinical cases covering 137 tumor types in our unique clinically validated PDx platform.
- The capability to generate additional data (e.g. genomics, transcriptomics etc.) from banked samples.
- A CLIA Laboratory with ongoing testing of live tumor tissue in our PDx assay
- The ability to reach-back to acquire patient clinical outcome data
- The latest, advanced artificial intelligence software developed by world-renowned researchers at Carnegie Mellon University

Revenue opportunity - partnership deals with BioPharma

- Biopharma AI deals are ranging from $5M, to over $1B, over several years with milestone, royalties etc
  - Typical $5M-$20M
    - Starts with a pilot study (typically $200K-$500K)
- Helomics is working to close pilots by end of 2020
- Small revenue stream from our clinical testing

Bayer and Exscientia collaborate to leverage the potential of artificial intelligence in cardiovascular and oncology drug discovery

Berlin, January 9, 2020 – Bayer and Exscientia Ltd., a UK-based Artificial Intelligence (AI)-driven drug discovery company, have entered into a three-year, multi-target collaboration. The partners will work on early research projects combining Exscientia's proprietary AI drug discovery platform and drug design know-how with Bayer's data and drug discovery capabilities. They aim to identify and optimize novel lead structures for potential drug candidates to treat cardiovascular and oncological diseases. Exscientia may be eligible to receive up to EUR 240 million, including upfront and research payments, near term and clinical milestones. As part of the

Summary

- Opportunity to invest in a company in a $1B, and growing, market with BioPharma keen to make deals

- Collaborative study with UPMC Magee Womens hospital demonstrates we can leverage the Helomics asset

- Helomics has the **data**, the **live tumor** platform, the **lab,** the access to **patient outcomes** and the **AI** to be a real disruptor

- $1Bn VC investment in AI drug discovery companies in 2018
  - Few if any public companies

TUMORGENESIS'S UNIQUE MEDIA'S, DISCOVERY KITS AND AI WILL TRANSFORM CANCER DIAGNOSIS AND TREATMENT

FOOLING CANCER CELLS TO BEHAVE AS IF THEY WERE STILL IN THE BODY WILL HELP ALL RESEARCHERS UNDERSTAND CANCER BETTER

TUMOR GENESIS

TumorGenesis is a wholly owned Subsidiary of Predictive Oncology, Inc. (NASDAQ: POAI)

TumorGenesis, Inc. 4 Technology Way, Salem, MA 01970   http://www.tumorgenesis.net
Contact: Richard Gabriel, BS, MBA; President; rgabriel@tumorgenesis.net; 781-883-6639

OUR SOLUTION:

DECREASE TIME, COST IN SCREENING PATIENTS WITH DRUG SCREENING

**IMPROVE ACCURACY AND RELIABILITY OF GROWING PATIENT DERIVED TUMORS**

EXPAND ACROSS MULTIPLE CANCERS WITH NEW MEDIA AND DISCOVERY KITS

LINK OUR PATIENT DERIVED TUMORS TO PATIENT THERAPIES WITH ARTIFICIAL INTELLIGENCE

COLLABORATE WITH GLOBAL GOVERNMENT AGENCIES FOCUSED ON DEFEATING CANCER

DEVELOP RELIABLE CANCER CELL CULTURES FOR DISCOVERY SERVICES WITH PHARMA AND BIOTECH

TumorGenesis is a wholly owned Subsidiary of Predictive Oncology, Inc. (NASDAQ: POAI)

2020
Launch Ovarian Cancer Media and Discovery Kits by End of 4th Quarter

USBio global distributors and TumorGenesis website

Revenue: $25K

2021
License and Launch Breast Cancer Media and Leukemia Media for AML

2nd Quarter

Pharma/gov. contracts

3rd Quarter

Full Year Revenue: $2MM

2022
Expand Cancer Models and Media to Colon, Pancreatic, Lung and Liver

2nd Quarter

Add additional Pharma/gov Contracts

Full Year Revenue $7MM

2023
License in additional technologies to expand product offerings

2nd Quarter

Add Pharma/gov contracts

Full Year Revenue $20MM

2024
Launch Global Initiative for the "Living Cancer Cell" bank

2nd Quarter

Add global Pharma/gov contracts

Full Year Revenue $40MM

TumorGenesis, Inc. 4 Technology Way, Salem, MA 01970   http://www.tumorgenesis.net
Contact: Richard Gabriel, BS, MBA; President; rgabriel@tumorgensis.net; 781-883-6639

TUMORGENESIS MEDIA AND CANCER CELLS WILL HELP CHANGE TREATMENT PROTOCOLS IN CANCER DISCOVERY, DEVELOPMENT AND TREATMENT

The Media, Cells and Discovery Kits from TumorGenesis will give Clinicians the Tools for better Patient Outcomes in the Future

Getting the Right Cell Types from Patient Derived Tumor Samples also means being able to Culture the Tumor Microenvironment

Biopsy Sample

TG Cancer Culture Discs- 1st Generation- 2021

Cell Separation can be done using TG Discovery Kits

Biomarkers Discovered using TG Discovery Kits also help Fool Cancer Cells that they are still in the patient

Heterogenous Tumor Cells   Macrophage   Cancer Stem Cell   Endothelial Cells   Blood Cells   Fibroblasts

TumorGenesis, Inc. 4 Technology Way, Salem, MA 01970   http://www.tumorgensis.net
Contact: Richard Gabriel, BS, MBA; President; rgabriel@tumorgensis.net; 781-883-6639

TumorGenesis, Inc. 4 Technology Way, Salem, MA 01970   http://www.tumorgenesis.net
Contact: Richard Gabriel, BS, MBA; President; rgabriel@tumorgensis.net; 781-883-6639

OUR PARTNERS

TumorGenesis is a wholly owned Subsidiary of Predictive Oncology, Inc. (NASDAQ: POAI)

TumorGenesis, Inc. 4 Technology Way, Salem, MA 01970   http://www.tumorgenesis.net
Contact: Richard Gabriel, BS, MBA; President; rgabriel@tumorgensis.net; 781-883-6639

SOLUBLE BIOTECH

OUR SOLUTION

- Decrease costs, time, and manpower required to optimize formulations via utilization of our Automated High Throughput Self-Interaction Chromatography (HSC™) Technology Platform

Competitors
- As much as year or more
- Hundreds of thousands of dollars
- Teams of ~5 or more

Value:

Optimization Steps with Our HSC™ Technology
- 3 months
- Tens of thousands of dollars
- One individual

Value:

COMPREHENSIVE FORMULATION SCREEN

Formulation Process

- Pre-Screen
- Initial Screen
- Discovery Screen
- Formulation Screen
- Delivery of Formulations

- Determine protein condition
- Optimize binding of protein to SIC media
- Identify minimal buffer

- Screen approximately 40 to 50 additives
- Determine 9 most promising additives

- Screen 36 conditions from 9 additives
- Determine *B* Values and relative solubility
- Confirm via dynamic laser light scattering
- Confirm conformational stability via differential scanning calorimetry

- Initial and Discovery Screen Analysis via NN
- Prediction of >4,000 formulations
- Confirmation of formulation *B* Values
- Confirmation of conformation stability via DSC

Pre-Screen → QC → Initial Screen → QC → Discovery → QC → Formulation → QC

ANNUAL REVENUE PROJECTIONS

- Rapidly determine FDA approved additives that will improve the solubility and stability of your protein in solution using our proprietary HSC technology
  - PROJECTED ANNUAL REVENUE = **$1.50+ million**

- Perform protein/drug stability evaluation (Forced Degradation Studies)
  - PROJECTED ANNUAL REVENUE = **$100,000+**

- Sale of Solubility and Stability Kits
  - PROJECTED ANNUAL REVENUE = **$50,000 +**

- NIH SBIR/STTR Grants
  - PROJECTED ANNUAL REVENUE = **$500,000**

  Total Project Revenue by December 2021 = 2.0 + million

Soluble has state-of-the-art equipment to evaluate drug stability as a result of temperature, light, humidity, physical stress and more

We have one SBIR ready for submission with two additional proposals scheduled for January submission

bdti

BioDtech, Inc.

Novel Solutions for Endotoxin Detection and Removal

Endotoxin Market

• The global recombinant protein market was valued at $347.2 million in 2016 with a CAGR of 6.2% to 2025.
• Approximately 30% of the recombinant pharmaceutical market is based on bacterial expression systems.

• These projects require strict endotoxin detection and removal technologies as dictated by the FDA.
• BioDtech, Inc. offers solutions for both removal and detection of endotoxin.

The Problem We Address

• Endotoxin is a molecule on the outer membrane of bacteria.

• Endotoxin is responsible for septic shock, which has a mortality rate of 40% and leads to 1.7 million deaths per year.

• BioDtech's EndoBind-R™ media specifically binds endotoxin and removes it from pharmaceutical proteins.

• BioDtech's EndoPrep™ treatment kit removes the inhibitory effects of proteins and allows accurate endotoxin detection.

Removal Technology

• BioDtech's EndoBind-R™ media specifically binds endotoxin and removes it from pharmaceutical proteins without product loss.

• EndoBind-R™ is based on the LAL assay, which is the gold standard of the FDA.

• EndoBind-R™ is available in a wide variety of sizes and in standard and single-use, disposable formats.

Detection Technology

• BioDtech's EndoPrep™ technology is used to remove the "masking" effects of recombinant proteins on endotoxin.

• EndoPrep™ eliminates false negatives, a significant issue in recombinant drugs.

• EndoPrep™ is an easy and fast companion to LAL testing, which is a $1.1 billion/year industry.

Endotoxin Masked by Protein and Undetectable

EndoPrep™

Endotoxin Liberated and Detectable

✸ Endotoxin   ⬭ Protein

SKYLINE MEDICAL

INVESTMENT HIGHLIGHTS

Manufacturer and marketer of the STREAMWAY® System, which solves the important challenge of medical waste fluid disposal in a safe, efficient and cost-effective manner

A product with numerous competitive features and benefits to healthcare professionals and patients, as well as a strong economic argument for hospitals and certain outpatient facilities

A strong presence in interventional radiology saving $80 - $100 per procedure

A hardware/disposables business model with a flexible sales model for the hardware and a potential $24,000 per year per unit in disposable sales

Distribution in place in U.S. and Internationally

More than 180 systems sold in the market